Europe Peptide Therapeutics Market Size & Outlook, 2026-2033
Global Market
Related Markets
Europe peptide therapeutics market highlights
- The Europe peptide therapeutics market generated a revenue of USD 27,916.3 million in 2025.
- The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.
- In terms of segment, metabolic disorders was the largest revenue generating application in 2025.
- Metabolic disorders is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Denmark is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 27,916.3 million |
| Market revenue in 2033 | USD 45,679.8 million |
| Growth rate | 5.5% (CAGR from 2026 to 2033) |
| Largest segment | Metabolic disorders |
| Fastest growing segment | Metabolic disorders |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gastrointestinal disorders, Cancer, Metabolic disorders, Cardiovascular disorders, Pain, Respiratory disorders, Infectious disease, Dermatological disorders, Renal disorders, Neurological disorders |
| Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Amgen Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Sanofi SA, Roche Holding AG, Novartis AG ADR, Novo Nordisk A/S ADR, GlaxoSmithKline, Ironwood Pharmaceuticals Inc Class A, Ipsen SA, Radius Health |
Other key industry trends
- In terms of revenue, Europe region accounted for 19.8% of the global peptide therapeutics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- North America is the fastest growing regional market and is projected to reach USD 199,806.7 million by 2033.
Europe held the second-largest market share in 2023 after North America and is estimated to grow at a lucrative CAGR over the forecast period. This growth can be attributed to increased research funding and the presence of key market players in this region. Increasing investments are driving the number of biopharmaceutical companies in Europe.
This population is at a relatively high risk of developing various target diseases, including cancer, cardiovascular diseases, & neurological disorders, as the risk of developing these conditions and hospitalization rates are relatively higher in elderly patients. Thus, owing to the abovementioned factors, the region is expected to witness exponential growth opportunities during the forecast period.
No credit card required*
Publish Date: Apr 20, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Peptide Therapeutics Market Scope
Peptide Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
Europe Peptide Therapeutics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Peptide Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Metabolic Disorders was the largest segment with a revenue share of 73.34% in 2025.
Horizon Databook has segmented the Europe peptide therapeutics market based on gastrointestinal disorders, cancer, metabolic disorders, cardiovascular disorders, pain, respiratory disorders, infectious disease, dermatological disorders, renal disorders, neurological disorders covering the revenue growth of each sub-segment from 2021 to 2033.
Europe held the second-largest market share in 2023 after North America and is estimated to grow at a lucrative CAGR over the forecast period. This growth can be attributed to increased research funding and the presence of key market players in this region. Increasing investments are driving the number of biopharmaceutical companies in Europe.
This population is at a relatively high risk of developing various target diseases, including cancer, cardiovascular diseases, & neurological disorders, as the risk of developing these conditions and hospitalization rates are relatively higher in elderly patients. Thus, owing to the abovementioned factors, the region is expected to witness exponential growth opportunities during the forecast period.
- Europe Peptide Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Cancer
- Metabolic disorders
- Cardiovascular disorders
- Respiratory disorders
- Gastrointestinal disorders
- Infectious disease
- Pain
- Dermatological disorders
- Neurological disorders
- Renal disorders
- Others
- Europe Peptide Therapeutics Market Type Outlook (Revenue, USD Million , 2021-2033)
- Generic
- Innovative
- Europe Peptide Therapeutics Market Type of Manufacturers Outlook (Revenue, USD Million , 2021-2033)
- Inhouse
- Outsourced
- Europe Peptide Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Parenteral Route
- Oral Route
- Pulmonary
- Mucosal
- Others
- Europe Peptide Therapeutics Market Synthesis Technology Outlook (Revenue, USD Million , 2021-2033)
- Recombinant DNA Technology
- Solid-Phase Peptide Synthesis (SPPS)
- Hybrid
- Liquid-Phase Peptide Synthesis (LPPS)
- Others
- Europe Peptide Therapeutics Market Type of Manufacturer Outlook (Revenue, USD Million , 2021-2033)
- Inhouse
- Outsourced
Reasons to subscribe to Peptide Therapeutics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Peptide Therapeutics Market Outlook databook
- Our clientele includes a mix of Peptide Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Peptide Therapeutics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Peptide Therapeutics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Peptide Therapeutics Market, 2021-2033 (US$M)
Europe peptide therapeutics market statistics, by application, 2021-2033 (US$M)
